Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Trial Profile

PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alglucosidase alfa (Primary) ; Elosulfase alfa (Primary) ; Galsulfase (Primary) ; Idursulfase (Primary) ; Laronidase (Primary) ; Sebelipase alfa (Primary) ; Vestronidase alfa (Primary)
  • Indications Lysosomal storage diseases
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PEARL
  • Most Recent Events

    • 11 Mar 2025 Planned End Date changed from 1 Jul 2032 to 31 Jul 2032.
    • 11 Mar 2025 Planned primary completion date changed from 1 Jul 2031 to 31 Jul 2031.
    • 16 Sep 2022 Planned End Date changed from 1 Apr 2032 to 1 Jul 2032.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top